Jeanne Mendell‐Harary

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

Koichiro Ogata, Jeanne Mendell‐Harary, Masaya Tachibana et al. · The Journal of Clinical Pharmacology · 2010 · 446 citations

Pharmacological Study, Medicine, Clinical Safety +10

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).

Todd M. Bauer, Mrinal M. Gounder, Amy Weise et al. · Journal of Clinical Oncology · 2018 · 43 citations

Chemoprevention Strategy, Cancer Management, Pathology +19

Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin

Ling He, Prachi Wickremasingha, James Lee et al. · Diabetes Research and Clinical Practice · 2014 · 23 citations

Pharmacological Study, Single-dose Pharmacokinetics, Pharmacology +5

Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).

Joachim von Pawel, Jennifer Tseng, Mircea Dediu et al. · Journal of Clinical Oncology · 2014 · 21 citations

Rheumatoid Disorder, Advanced Nsclc Subjects, P Safety +15

Nonlinear in Vitro-in Vivo Correlations

Jeanne Mendell‐Harary, James A. Dowell, Sian Bigora et al. · Advances in experimental medicine and biology · 1997 · 18 citations

Mechanobiology, Vitro-in Vivo Correlations, In Vivo System +4